Ponezumab - Misplaced Pages

This is an old revision of this page, as edited by CheMoBot (talk | contribs) at 09:39, 1 November 2011 (Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacol...). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 09:39, 1 November 2011 by CheMoBot (talk | contribs) (Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacol...)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound

Ponezumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	beta-amyloid
Clinical data
ATC code	none
Identifiers
CAS Number	1178862-65-1
ChemSpider	NA
UNII	1TG15H1XE9
Chemical and physical data
Formula	C₆₅₅₂H₁₀₁₅₈N₁₇₃₀O₂₀₉₀S₅₂
Molar mass	148.3 kDa g·mol
(what is this?) (verify)

Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer's disease.

Ponezumab was developed by Pfizer Inc.

References

"Statement On A Nonproprietary Name Adopted By The USAN Council: Ponezumab" (PDF). American Medical Association.

Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems

Bone

Human	Burosumab Denosumab
Humanized	Blosozumab Romosozumab

Musculoskeletal

Human	Stamulumab

Circulatory

Human	Abelacimab Alirocumab Ascrinvacumab Bentracimab Enoticumab Evinacumab Evolocumab Icrucumab Inclacumab Marstacimab Nesvacumab Orticumab Ramucirumab Rinucumab
Mouse	Biciromab Imciromab
Chimeric	Abciximab Volociximab
Humanized	Alacizumab pegol Bevacizumab/Ranibizumab Bococizumab Brolucizumab Caplacizumab Concizumab Demcizumab Emicizumab Etaracizumab Faricimab Idarucizumab Ralpancizumab Tadocizumab Vanucizumab

Neurologic

Human	Anti-amyloid drugs Aducanumab Donanemab Gantenerumab Lecanemab Erenumab Fasinumab Fulranumab Opicinumab
Humanized	Bapineuzumab Crenezumab Eptinezumab Fremanezumab Galcanezumab Ozanezumab Ponezumab Refanezumab Semorinemab Solanezumab Tanezumab

Angiogenesis inhibitor

Humanized	Ranibizumab

Growth factor

Human	Bimagrumab Trevogrumab
Humanized	Domagrozumab Landogrozumab

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it.

Categories: